GWM
BPMC

Geneos Wealth Management’s Blueprint Medicines BPMC Stock Holding History

Geneos Wealth Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-23
Closed -$2.95K – 2575
2025
Q2 		$2.95K Buy
23
+7
+44% +$727 ﹤0.01% 2726
2025
Q1 		$1.42K Buy
+16
New +$1.56K ﹤0.01% 3019
2021
Q3 		– Sell
-100
Closed -$8K – 2841
2021
Q2 		$8K Hold
100
– – ﹤0.01% 2269
2021
Q1 		$9K Hold
100
– – ﹤0.01% 2408
2020
Q4 		$9K Hold
100
– – ﹤0.01% 2242
2020
Q3 		$8K Hold
100
– – ﹤0.01% 2015
2020
Q2 		$7K Hold
100
– – ﹤0.01% 2029
2020
Q1 		$5K Buy
+100
New +$6.43K ﹤0.01% 2013
2019
Q1 		– Sell
-150
Closed -$7K – 2410
2018
Q4 		$7K Hold
150
– – ﹤0.01% 1869
2018
Q3 		$11K Buy
+150
New +$10.4K ﹤0.01% 1801

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Geneos Wealth Management's BPMC Position: Q3 2025 in Review

Geneos Wealth Management sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 23 shares — an estimated $2.95K sold.

Geneos Wealth Management first reported a position in BPMC in Q3 2018 and held it in 10 quarters. The position peaked at $11K in Q3 2018. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Geneos Wealth Management reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Geneos Wealth Management sold 23 Blueprint Medicines shares in Q3 2025, an estimated $2.95K.
  • Geneos Wealth Management first reported a position in Blueprint Medicines in Q3 2018 and held it in 10 quarters.
  • Geneos Wealth Management's Blueprint Medicines position peaked at $11K in Q3 2018.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Geneos Wealth Management's 13F filing for Q3 2025, filed 22 Oct 2025.